

INFORMAZIONI PERSONALI **Alessandro De Toma**

Nazionalità Italiana

ESPERIENZE LAVORATIVE

- 16/01/2024-Presente **Dirigente Medico in Oncologia**
ASST Santi Paolo & Carlo, Ospedale San Paolo, Milano (Italia)
- 01/01/2023–15/01/2024 **Dirigente Medico in Oncologia**
ASST Sette Laghi, Ospedale di
Circolo e Fondazione Macchi
(Varese)
- 21/01/2020–21/12/2022 **Collaborazione professionale specialistica in Oncologia Medica (Oncologia Toracica)**
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano (Italia) –
Dipartimento di Oncologia Medica
- 01/12/2019–09/12/2019 **Formazione specialistica in Oncologia Medica**
Università degli studi di Verona
Piazzale L.A. Scuro 10, Verona (Italia)
- 01/12/2018–30/11/2019 **Formazione specialistica in Oncologia Medica presso divisione di Oncologia Toracica**
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano - Dipartimento di Oncologia
Medica diretta dal prof. Filippo de Braud, supervisore dott.ssa Marina Chiara Garassino
Via G. Venezian 1, Milano (Italia)
- 09/12/2014–30/11/2018 **Formazione specialistica in Oncologia Medica**
Università degli Studi di Verona
Piazzale L.A. Scuro 10, Verona (Italia)
- 01/02/2014–31/08/2014 **Medico Abilitato in frequentazione volontaria**
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano - Divisione di Ematologia e
Trapianto di midollo osseo
Via G. Venezian 1, Milano (Italia)
- 01/09/2011–15/10/2013 **Internato a scopo di tesi**
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano - Divisione di Ematologia e
trapianto di midollo osseo
Via G. Venezian 1, Milano (Italia)

EDUCAZIONE E FORMAZIONE

- 12/12/2019 **Specializzazione in Oncologia Medica**
Università degli Studi di Verona, Verona (Italia)
Tesi: "Iperprogressione di malattia dopo immune checkpoints inhibitors in pazienti con
NSCLC avanzato: criteri di valutazione a confronto"

Curriculum vitae

Supervisor: professor Michele Milella

70/70 cum laude

06/03/2014 **Abilitazione all'esercizio della professione medica e completamento esame di stato per l'Italia**

Ordine dei Medici e Chirurghi di Bergamo, Bergamo (Italia)

16/10/2013 Laurea Magistrale a ciclo unico in Medicina & Chirurgia

Università degli Studi di Milano, Milano (Italia)

Tesi: "Monitoraggio delle troponine e di parametri ecocardiografici innovativi come predittori di cardiotoxicità in pz affetti da linfoma non Hodgkin a cellule B e linfoma di Hodgkin trattati con antracicline o chemioterapia ad alte dosi: studio prospettico"

Supervisor: professor Paolo Corradini

110/110 cum laude

06/07/2007 Diploma di Scuola Superiore

Liceo Scientifico L. Mascheroni, Bergamo (Italia)

ABILITA' PERSONALI

Lingua Madre Italiano

Lingue Straniere

English

UNDERSTANDING		SPEAKING		WRITING
Listening	Reading	Spoken interaction	Spoken production	
C1	C2	C1	C1	B2

Levels: A1 and A2: Basic user - B1 and B2: Independent user - C1 and C2: Proficient user
Common European Framework of Reference for Languages - Self-assessment grid

Patente di guida B

ULTERIORI INFORMAZIONI

Pubblicazioni

- 1) Zambonin V, **De Toma A**, Carbognin L, Nortilli R, Fiorio E, Parolin V, Pilotto S, Cuppone F, Pellini F, Lombardi D, Pollini GP, Tortora G, Bria E. Clinical results of randomized trials and 'real-world' data exploring the impact of bevacizumab for breast cancer: opportunities for clinical practice and perspectives for research. *Expert Opin Biol Ther* 2017; 17(4): 497-506
- 2) Trestini I, Carbognin L, Monteverdi S, Zanelli S, **De Toma A**, Bonaiuto C, Nortilli F, Fiorio E, Pilotto S, Di Maio M, Gasbarrini A, Scambia G, Tortora G, Bria E. Clinical implication of changes in body composition and weight in patients with early-stage and metastatic breast cancer. *Crit Rev Oncol/hematol* 2018; 129:54-66
- 3) Galli G, Proto C, Signorelli D, Imbimbo M, Ferrara R, Prelaj A, **De Toma A**, Ganzinelli M, Zilembo N, de Braud F, Garassino MC, Lo Russo G. Characterization of patients with metastatic non-small-cell lung cancer obtaining long-term benefit from immunotherapy. *Future Oncol* 2019; 15(23): 2743-2757
- 4) Galli G, **De Toma A**, Pagani F, Randon G, Trevisan B, Ferrara R, Prelaj A, Proto C, Signorelli D, Ganzinelli M, Zilembo N, de Braud F, Garassino MC, Lo Russo G. Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer. *Lung Cancer* 2019; 137:38-42
- 5) Prelaj A, Ferrara R, Rebuzzi SE, Proto C, Signorelli D, Galli G, **De Toma A**, Randon G, Pagani F, Viscardi G, Brambilla M, Trevisan B, Ganzinelli M, Martinelli A, Galluci R, Di Mauro RM, Molino G, Zilembo N, Tori V, de Braud FM, Garassino MC, Lo Russo G. EPSiLoN: a prognostic score for immunotherapy in advanced non-small cell lung cancer: a validation cohort. *Cancers* 2019; 11(12):1954
- 6) Metro G, Addeo A, Signorelli D, Gili A, Economopoulou P, Roila F, Banna G, **De Toma A**, Rey Cobo J, Camerini A, Christopoulou A, Lo Russo G, Banini M, Galetta D, Jimenez B, Collazo-Lorduy A, Calles A, Baxevasos P, Linardou H, Kosmidis P, Garassino MC, Mountzios G. Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1≥50% who progress on first-line immunotherapy: real-world data from a European cohort. *J Thorac Dis* 2019; 11(12): 4972-4981
- 7) Petrelli F, Signorelli D, Ghidini M, Ghidini A, Pizzutilo EG, Ruggieri L, Cabiddu M, Borgonovo K, Dognini G, Brighenti M, **De Toma A**, Rijavec E, Garassino MC, Grossi F, Tomasello G. Association of steroids use with survival in patients treated with immune checkpoint inhibitors: a systematic review

and meta-analysis. *Cancers* 2020; 12(3):546

- 8) Prelaj A, Lo Russo G, Proto C, Signorelli D, Ferrara R, Galli G, **De Toma A**, Randon G, Pagani F, Trevisan B, Ganzinelli M, Zilembo N, Montrone M, Longo V, Pesola F, Pizzutilo P, Del Bene G, Varesano N, Galetta D, Torri V, Garassino MC, Di Maio M, Catino A. DiM: prognostic score for second- or further-line immunotherapy in advanced non-small-cell lung cancer: an external validation. *Clin Lung Cancer* 2020; 7:S1525-7304(20)30005
- 9) Whisenant JG, Trama A, Torri V, **De Toma A**, Viscardi G, Cortellini A, Micheilin O, Barlesi F, Dingemans AC, Van Meerbeeck J, Pancaldi V, Soo RA, Leighl NB, Peters S, Wakelee H, Garassino MC, Horn L. TERA-VOLT: Thoracic Cancers International COVID-19 Collaboration. *Cancer Cell* 2020; 37(6): 742-745
- 10) Friedlaender A, Metro G, Signorelli D, Gili A, Economopoulou P, Roila F, Banna G, **De Toma A**, Camerini A, Christopoulou A, Lo Russo G, Banini M, Galetta D, Jimenez B, Collazo-Lorduy A, Calles A, Baxevanos P, Linardou H, Kosmidis P, Mountzios G, Garassino MC, Addeo A. Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumor proportion score $\geq 50\%$ treated with front-line pembrolizumab. *Acta Oncol* 2020; 59(9): 1058-1063
- 11) Prelaj A, Proto C, Lo Russo G, Signorelli D, Ferrara R, Mensah M, Galli G, **De Toma A**, Viscardi G, Brambilla M, Lobefaro R, Trevisan B, Trovò F, Torri V, Sozzi G, Garassino MC, Boeri M. Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMO score system. *Transl Lung Cancer* 2020; 9(3):617-628
- 12) Garassino MC, Whisenant JG, Huang LC, Trama A, Torri V, Agustoni F, Baena J, Banna G, Berardi R, Bettini AC, Bria E, Brighenti M, Cadranet J, **De Toma A**, Chini C, Cortellini A, Felip E, Finocchiaro G, Garrido P, Genova C, Giusti R, Gregorc V, Grossi F, Grosso F, Intagliata S, La Verde N, Liu SV, Mazieres J, Mercadante E, Michielin O, Minuti G, Moro-Sibilot D, Pasello G, Passaro A, Scotti V, Solli P, Stroppa E, Tiseo M, Viscardi G, Voltolini L, Wu YL, Zai S, Pancaldi V, Dingemans AM, Van Meerbeeck J, Barlesi F, Wakelee H, Peters S, Horn L; TERA-VOLT investigators. COVID-19 in patients with thoracic malignancies (TERA-VOLT): first results of an International, registry-based, cohort study. *Lancet Oncol* 2020; 21(7): 914-922
- 13) Cortellini A, Ricciuti B, Tiseo M, Bria E, Banna GL, Aerts JG, Barbieri F, Giusti R, Cortinovis DL, Migliorino MR, Catino A, Passiglia F, Torniai M, Morabito A, Genova C, Mazzoni F, Di Noia V, Signorelli D, Gelibter A, Occhipinti MA, Rastelli F, Chiari R, Rocco D, Inno A, De Tursi M, Di Marino P, Mansueto G, Zoratto F, Grossi F, Filetti M, Pizzutilo P, Russano M, Citarella F, Cantini L, Targato G, Nigro O, Ferrara MG, Buti S, Scodes S, Landi L, Guaitoli G, Della Gravara L, Tabbò F, Ricciardi S, **De Toma A**, Friedlaender A, Petrelli F, Addeo A, Porzio G, Ficorella C. Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with PD-L1 expression $\geq 50\%$: a multi center study with external validation. *J Immunother Cancer* 2020; 8(2): e001403
- 14) Metro G, Banna GL, Signorelli D, Gili A, Galetta D, Galli G, Economopoulou P, Roila F, Friedlaender A, Camerini A, Christopoulou A, Cantale O, **De Toma A**, Pizzutilo P, Jimenez B, Collazo-Lorduy A, Calles A, Baxevanos P, Linardou H, Kosmidis P, Giannarelli D, Mountzios G, Addeo A. Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metastases From Advanced Non-Small Cell Lung Cancer With a PD-L1 Expression $\geq 50\%$. *J Immunother* 2020; 43(9): 299-306
- 15) Cortellini A, Friedlaender A, Banna GL, Porzio G, Bersanelli M, Cappuzzo F, Aerts JGJV, Giusti R, Bria E, Cortinovis D, Grossi F, Migliorino MR, Galetta D, Passiglia F, Berardi R, Mazzoni F, Di Noia V, Signorelli D, Tuzi A, Gelibter A, Marchetti P, Macerelli M, Rastelli F, Chiari R, Rocco D, Inno A, Di Marino P, Mansueto G, Zoratto F, Santoni M, Tudini M, Ghidini M, Filetti M, Catino A, Pizzutilo P, Sala L, Occhipinti MA, Citarella F, Marco R, Torniai M, Cantini L, Follador A, Sforza V, Nigro O, Ferrara MG, D'Argento E, Leonetti A, Pettoruti L, Antonuzzo L, Scodes S, Landi L, Guaitoli G, Baldessari C, Bertolini F, Della Gravara L, Dal Bello MG, Belderbos RA, De Filippis M, Cecchi C, Ricciardi S, Donisi C, **De Toma A**, Proto C, Addeo A, Cantale O, Ricciuti B, Genova C, Morabito A, Santini D, Ficorella C, Cannita K. Immune-related adverse events of pembrolizumab in a large real-world cohort of patients with NSCLC with PD-L1 expression $\geq 50\%$ and their relationship with clinical outcomes. *Clin Lung Cancer*; 21(6): 498-508

- 16) Banna GL, Signorelli D, Metro G, Galetta D, **De Toma A**, Cantale O, Banini M, Friedlaender A, Pizzutillo P, Garassino MC, Addeo A. Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarker for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumab. *Transl Lung Cancer* 2020; 9(4):1533-1542
- 17) Cortellini A, Tiseo M, Banna GL, Cappuzzo F, Aerts JGJV, Barbieri F, Giusti R, Bria E, Cortinovis D, Grossi F, Migliorino MR, Galetta D, Passiglia F, Santini D, Berardi R, Morabito A, Genova C, Mazzoni F, Di Noia V, Signorelli D, Tuzi A, Gelibter A, Marchetti P, Macerelli M, Rastelli F, Chiari R, Rocco D, Gori S, De Tursi M, Mansueto G, Zoratto F, Santoni M, Tudini M, Rijavec E, Filetti M, Catino A, Pizzutillo P, Sala L, Citarella F, Marco R, Torniai M, Cantini L, Targato G, Sforza V, Nigro O, Ferrara MG, D'Argento E, Buti S, Bordi P, Antonuzzo L, Scodes S, Landi L, Guaitoli G, Baldessari C, Della Gravara L, Dal Bello MG, Belderbos RA, Bironzo P, Carnio S, Ricciardi S, Grieco A, **De Toma A**, Proto C, Friedlaender A, Cantale O, Ricciuti B, Addeo A, Metro G, Ficorella C, Porzio G. Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and PD-L1 expression of $\geq 50\%$. *Cancer Immunol Immunother* 2020; 69 (11): 2209-2221
- 18) Signorelli D, Proto C, Botta L, Trama A, Tiseo M, Pasello G, Lo Russo G, Fabbri A, Imbimbo M, Busico A, Prelaj A, Ferrara R, Galli G, **De Toma A**, Tamborini E, Pastorino U, de Braud F, Gatta G, Garassino MC, Ganzinelli M. SMO mutations confer poor prognosis in malignant pleural mesothelioma. *Transl Lung Cancer* 2020; 9(5): 1940-1951
- 19) Mountzios G, **De Toma A**, Economopoulou P, Friedlaender A, Banini M, Lo Russo G, Baxevanos P, Roila F, Banna GL, Christopoulou A, Jimenez B, Collazo-Lorduy A, Linardou H, Calles A, Galetta D, Addeo A, Camerini A, Pizzutillo P, Kosmidis P, Garassino MC, Proto C, Signorelli D, Metro G. Steroid use independently predicts for poor outcomes in patients with advanced NSCLC and high PD-L1 expression receiving first-line pembrolizumab immunotherapy. *Clin Lung Cancer* 2020; S1525-7304(20)30297-7
- 20) **De Toma A**, Lo Russo A, Signorelli D, Ferrara R, Prelaj A, Galli G, Viscardi G, Trevisan B, Ganzinelli M, Zilembo N, de Braud F, Garassino MG, Proto C. Facing the first-line in metastatic non-small-cell lung cancer: immunotherapy and chemotherapy. *European oncology and haematology* 2020; 16(1):39-43
- 21) Lobefaro R, Viscardi G, Di Liello R, Massa G, Iacovino ML, Sparano F, Della Corte CM, Ferrara R, Signorelli D, Proto C, Prelaj A, Galli G, **De Toma A**, Brambilla M, Ganzinelli M, Trevisan B, Ciardiello F, de Braud FM, Morgillo F, Garassino MC, Lo Russo G. Immunotherapy in advanced non-small cell lung cancer patients with poor performance status: the role of clinical-pathological variables and inflammatory biomarkers. *Lung Cancer* 2021; 152: 165-173
- 22) Cortellini A, De Giglio A, Cannita K, Cortinovis DL, Cornelissen R, Baldessari C, Giusti R, D'Argento E, Grossi F, Santoni M, Catino A, Berardi R, Sforza V, Rossi G, Antonuzzo L, Di Noia V, Signorelli D, Gelibter A, Occhipinti MA, Follador A, Rastelli F, Chiari R, Gravara LD, Inno A, De Tursi M, Di Marino P, Mansueto G, Zoratto F, Filetti M, Montrone M, Citarella F, Pensieri MV, Russano M, Cantini L, Nigro O, Leonetti A, Bordi P, Minuti G, Landi L, **De Toma A**, Donisi C, Ricciardi S, Migliorino MR, Napoli VM, Leone G, Metro G, Banna GL, Friedlaender A, Addeo A, Ficorella C, Porzio G. Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: a case-control matched analysis from a large multicenter study. *Thorac Cancer* 2021; 12(6):880-889
- 23) Viscardi G, Di Natale D, Fasano M, Brambilla M, Lobefaro R, **De Toma A**, Galli G. Circulating biomarkers in malignant pleural mesothelioma. *Explor Target Antitumor Ther* 2020; 1:434.451
- 24) Cortellini A, Cannita K, Tiseo M, Cortinovis DL, Joachim Aerts GJV, Baldessari C, Giusti R, Ferrara MG, D'Argento E, Grossi F, Guida A, Berardi R, Morabito A, Genova C, Antonuzzo L, Mazzoni F, **De Toma A**, Signorelli D, Gelibter A, Targato G, Rastelli F, Chiari R, Rocco D, Gori S, De Tursi M, Mansueto G, Zoratto F, Filetti M, Bracarda S, Citarella F, Russano M, Cantini L, Nigro O, Buti S, Minuti G, Landi L, Ricciardi S, Migliorini MR, Natalizio S, Carnio S, De Filippis Marco, Metro G, Adamo V, Russo A, Spinelli GP, Di Maio M, Banna GL, Friedlaender A, Addeo A, Pinato DJ, Ficorella C, Porzio G. Post-progression outcomes of NSCLC patients with PD-L1 expression $\geq 50\%$ receiving first-line single-agent pembrolizumab in a large multicentre real-world study. *European Journal of Cancer* 2021; 148: 24-35

- 25) **De Toma A**, Lo Russo G, Signorelli D, Pagani F, Randon G, Galli G, Prelaj A, Ferrara R, Proto C, Ganzinelli M, Zilembo N, de Braud F, Garassino MC. Uncommon targets in non-small cell lung cancer: everyone wants a slice of cake. *Crit Rev Oncol Ematol* 2021; 160
- 26) Prelaj A, Pircher CC, Massa G, Martelli V, Corrao G, Lo Russo G, Proto C, Ferrara R, Galli G, **De Toma A**, Genova C, Jereczek-Fossa BA, de Braud F, Garassino MC, Rebuzzi SE. Beyond first-line immunotherapy: potential therapeutic strategies based on different pattern progressions: oligo and sistemyc progression. *Cancers* 2021; 13, 1300.
- 27) Metro G, Gili A, Signorelli D, **De Toma A**, Garaffa M, Galetta D, Economopoulou P, Friedlander A, Jimenez B, Collazo-Lorduy A, Addeo A, Chirini P, Costa C, Mountzios G, Roila F. Upfront pembrolizumab as an effective treatment start in patient with PD-L1 $\geq 50\%$ non-oncogene addicted non-small cell lung cancer and asymptomatic brain metastases: an exploratory analysis. *Clin Transl Oncol* 2021; 23(9): 1818-1826
- 28) Cortellini A, Di Maio M, Nigro O, Leonetti A, Cortinovis DL, Aerts JG, Guaitoli G, Barbieri F, Giusti R, Ferrara MG, Bria E, D'Argento E, Grossi F, Rijavec E, Guida A, Berardi R, Torniai M, Sforza V, Genova C, Mazzoni F, Garassino MC, **De Toma A**, Signorelli D, Gelibter A, Siringo M, Marchetti P, Macerelli M, Rastelli F, Chiari R, Rocco D, Della Gravara L, Inno A, Michele T, Grassadonia A, Di Marino P, Mansueto G, Zoratto F, Filetti M, Santini D, Citarella F, Russano M, Cantini L, Tuzi A, Bordi P, Minuti G, Landi L, Ricciardi S, Migliorino MR, Passiglia F, Bironzo P, Metro G, Adamo V, Russo A, Spinelli GP, Banna GL, Friedlander A, Addeo A, Cannita K, Ficorella C, Porzio G, Pinato DJ. Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy. *J Immunother cancer* 2021; 9(4):e00241
- 29) Banna GL, Cortellini A, Cortinovis DL, Tiseo M, Aerts JGJV, Barbieri F, Giusti R, Bria E, Grossi F, Pizzutilo B, Berardi R, Morabito A, Genova C, Mazzoni F, Di Noia V, Signorelli D, Gelibter A, Macerelli M, Rastelli F, Chiari R, Rocco D, Gori S, De Tursi M, Di Marino P, Mansueto G, Zoratto F, Filetti M, Montrone M, Citarella F, Marco R, Cantini L, Nigro O, D'Argento E, Buti S, Minuti G, Landi L, Guaitoli G, Lo Russo G, **De Toma A**, Donisi C, Friedlander A, De Giglio A, Metro G, Porzio G, Ficorella C, Addeo A. The lung immunology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 $\geq 50\%$ advanced non-small cell lung cancer. *ESMO Open* 2021; 6(2): 100078
- 30) Prelaj A, Bottiglieri A, Proto C, Lo Russo G, Signorelli D, Ferrara R, Galli G, **De Toma A**, Viscardi G, Brambilla M, Lobefaro R, Nichetti F, Manglaviti S, Occhipinti M, La Bianca A, Ganzinelli M, Gallucci R, Zilembo N, Greco GF, Torri V, de Braud F, Garassino MC. Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: results from the expanded access program. *Eur J Cancer* 2021; 149: 235-248
- 31) Buti S, Bersanelli M, Perrone F, Bracarda S, Di Maio M, Giusti R, Nigro O, Cortinovis DL, Aerts JGJV, Guaitoli G, Barbieri F, Ferrara MG, Bria E, Grossi F, Bareggi C, Berardi R, Torniai M, Cantini L, Sforza V, Genova C, Chiari R, Rocco D, Della Grava L, Gori S, De Tursi M, Di Marino P, Mansueto G, Zoratto F, Filetti M, Citarella F, Russano M, Mazzoni F, Garassino MC, **De Toma A**, Signorelli D, Gelibter A, Siringo M, Follador A, Bissoni R, Tuzi A, Minuti G, Landi L, Ricciardi S, Migliorino MR, Tabbò F, Olmetto E, Metro G, Adamo V, Russo A, Spinelli GP, Banna GL, Addeo A, Friedlander A, Cannita K, Porzio G, Ficorella C, Carmisciano L, Pinato DJ, Mazzaschi G, Tiseo M, Cortellini A. Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy. *Eur J Cancer* 2021; 150:224-231
- 32) Bertolini G, Cancila V, Milione M, Lo Russo G, Fortunato O, Zaffaroni N, Tortoreto M, Centonze G, Chiodoni C, Facchinetti F, Pollaci G, Taiè G, Giovino F, Moro M, Camisaschi C, **De Toma A**, D'Alterio C, Pastorino U, Tripodo C, Scala S, Sozzi G, Roz L. A novel CXCR4 antagonist counteracts paradoxical generation of cisplatin-induced pro-metastatic niches in lung cancer. *Mol Ther* 2021; S1525.0016(21)0026-5
- 33) Manglaviti S, Brambilla M, Signorelli D, Ferrara R, Lo Russo G, Proto C, Galli G, **De Toma A**, Occhipinti M, Viscardi G, Beninato T, Zattarin E, Bini M, Lobefaro R, Massa G, Bottiglieri A, Apollonio G, Sottotetti E, Di Mauro RM, Trevisan B, Ganzinelli M, Fabbri A, De Braud FGM, Garassino M, Prelaj A. Immune-checkpoint inhibitors in advanced non-small cell lung cancer with uncommon histology. *Clin Lung Cancer* 2021; S1525-7304(21)00180-7

- 34) Occhipinti M, Brambilla M, Galli G, Manglaviti S, Giammaruco M, Prelaj A, Ferrara R, **De Toma A**, Proto C, Beninato T, Zattarin E, Lo Russo G, Gelibter AJ, Simmaco M, Preissner R, Garassino MC, De Braud F, Marchetti P. Evaluation of drug-drug interactions in EGFR-mutated non-small cell lung cancer patients during treatments with tyrosine-kinase inhibitors. *J Pers Med* 2021; 11(5):424
- 35) Prelaj A, Boeri M, Robuschi A, Ferrara R, Proto C, Lo Russo G, Galli G, **De Toma A**, Brambilla M, Occhipinti M, Manglaviti S, Beninato T, Bottiglieri A, Massa G, Zattarin E, Gallucci R, Galli EG, Ganzinelli M, Sozzi G, De Braud FGM, Garassino MC, Restelli M, Pedrocchi ALG, Trovo' F. Machine learning using real-world and translational data to improve treatment selection for NSCLC patients treated with immunotherapy. *Cancers* 2022; 14(2): 435.
- 36) Banna GL, Tiseo M, Cortinovis D, Facchinetti F, Aerts JGJV, Baldessari C, Giusti R, Bria E, Grossi F, Berardi R, Morabito A, Catino A, Genova C, Mazzoni F, Gelibter A, Rastelli F, Macerelli M, Chiari R, Gori S, Mansueto G, Citarella F, Cantini L, Rijavec E, Bertolini F, Capuzzo F, **De Toma A**, Friedlander A, Metro G, Pensieri MV, Porzio G, Ficorella C, Pinato DJ, Cortellini A, Addeo A. Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 $\geq 50\%$ metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapy. *Thorac Cancer* 2021; 13(3):483-488.
- 37) Cantini L, Mentrasti G, Russo GL, Signorelli D, Pasello G, Rijavec E, Russano M, Antonuzzo L, Rocco D, Giusti R, Adamo V, Genova C, Tuzi A, Morabito A, Gori S, Verde N, Chiari R, Cortellini A, Cognigni V, Pecci F, Indini A, **De Toma A**, Zattarin E, Oresti S, Pizzuttilo EG, Frega S, Erbetta E, Galletti A, Citarella F, Fancelli S, Caliman E, Della Gravara L, Malapelle U, Filetti M, Piras M, Toscano G, Zullo L, De Tursi M, Di Marino P, D'Emilio V, Cona MS, Guida A, Caglio A, Salerno F, Spinelli G, Bennati C, Morgillo F, Russo A, Dellepiane C, Vallini I, Sforza V, Inno A, Rastelli F, Tassi V, Nicolardi L, Pensieri V, Emili R, Roca E, Migliore A, Galassi T, Rocchi MLB, Berardi R. Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario. *ESMO Open* 2022; 7(2): 100406
- 38) Bestvina CM, Whisenant JG, Torri V, Cortellini A, Wakelee H, Peters S, Roca E, **De Toma A**, Hirsch FR, Mamdani H, Halmos B, Arrieta O, Metivier AC, Fidler MJ, Rogado J, Presley CJ, Mascaux C, Genova C, Blaquier JB, Addeo A, Finocchiaro G, Khan H, Mazieres J, Morgillo F, Bar J, Aujayeb A, Mountzios G, Scotti V, Grosso F, Geraedts E, Zhumagaliyeva AN, Horn L, Garassino MC, Baena J. COVID-19 outcomes, patient vaccination status, and cancer-related delays during the omicron wave: a brief report from the TERAVOLT analysis. *JTO Clin Res Rep* 2022; 100335.
- 39) Galli G, Corsetto PA, Proto C, Lo Russo G, Ganzinelli M, Rulli E, Legramandi L, Morelli D, Ferrara R, Prelaj A, Signorelli D, **De Toma A**, Brambilla M, Occhipinti M, Manglaviti S, Boeri M, Martinetti A, Vingiani A, Colombo MP, Rizzo AM, Torri V, de Braud F, Sangaletti S, Sica A, Garassino MC. Circulating fatty acid profile as a biomarker for immunotherapy in advanced non-small cell lung cancer. *Clin Lung Cancer* 2022; S1525-7304(22)00155-3
- 40) Prelaj A, Bottiglieri A, Bhat J, Washington R, Calareso G, Greco GF, Ferrara R, Brambilla M, **De Toma A**, Occhipinti M, Manglaviti S, Soro A, Ganzinelli M, Lo Russo G, Proto C. Case report: exceptional response to poziotinib in patients with metastatic non-small cell lung cancer with exon 20 insertion mutation. *Front Oncol* 2022; 12:902697
- 41) Zattarin E, Manglaviti S, Apollonio G, Beninato T, Mazzeo L, Massa G, Bottiglieri A, Galli E, **De Toma A**, Occhipinti M, Brambilla M, Ferrara R, Ganzinelli M, Proto C, Garassino MC, de Braud F, Lo Russo G, Prelaj A. Prognostic role of neutrophil-to-lymphocyte ratio and EPSILON score in advanced non-small-cell lung cancer patients treated with first-line immunotherapy. *Future Oncol* 2022; 18(23):2593-2604.
- 42) Signorelli D, Ghidotti P, Proto C, Brambilla M, **De Toma A**, Ferrara R, Galli G, Ganzinelli M, Lo Russo G, Prelaj A, Occhipinti M, Viscardi G, Capizzuto V, Pontis F, Petrarola I, Ferretti AM, Colombo MP, Torri V, Sozzi G, Garassino MC, Jachetti E, Fortunato O. Circulating CD-81 expressing extracellular vesicles as biomarker of response for immune-checkpoint inhibitors in advanced NSCLC. *Front Immunol* 2022; 13:987639

- 1) Signorelli D, Ferrara R, Proto C, Lo Russo G, Imbimbo M, Galli G, **De Toma A**, Pagani F, Randon G, Fucà G, Trevisan B, Ganzinelli M, Zilembo N, Fabbri A, De Braud F, Garassino MC, Prelaj A. Immune-checkpoints inhibitors in metastatic non small cell lung cancer with rare histology. Abstract 9106 (270539) (Accepted as poster at ASCO 2019)
- 2) Galli G, Corsetto PA, Ferrara R, Prelaj A, Proto C, Signorelli D, Zilembo N, **De Toma A**, Pagani F, Randon G, Ganzinelli M, Sica A, de Braud F, Garassino MC, Lo Russo G. Impact of cholesterolemia and body mass index on outcome of metastatic non small cell lung cancer treated with immunotherapy. (Accepted as ABSTRACT at ASCO 2019)
- 3) Prelaj A, Lo Russo G, Proto C, Signorelli D, Ferrara R, Galli G, **De Toma A**, Randon G, Zilembo N, Trevisan B, Montrone M, Longo V, Pesola F, Varesano N, Del Bene G, Pizzutilo P, Galetta D, Garassino MC, Di Maio M, Catino AM. Prognostic score for second or further line immunotherapy in advanced non-small cell lung cancer (aNSCLC): An external validation. (Accepted as ABSTRACT at ASCO 2019)
- 4) Prelaj A, Lo Russo G, Signorelli D, Ferrara R, Imbimbo M, Galli G, **De Toma A**, Randon G, Brambilla M, Ganzinelli M, Zilembo N, de Braud F, Garassino MC, Proto C. EPSILON score: validation cohort of a prognostic score in advanced non-small cell lung cancer (aNSCLC) patients treated with immunotherapy (Accepted as poster at ESMO 2019)
- 5) Prelaj A, Proto C, Lo Russo G, Signorelli D, Ferrara R, Galli G, **De Toma A**, Randon G, Pagani F, Trevisan B, Ganzinelli M, Zilembo N, de Braud FMG, Mensah M, Torri V, Garassino MC, Sozzi G, Boeri M. DEMO: a prospective evaluation of a prognostic clinico-molecular composite score in NSCLC patients treated with immunotherapy. (Accepted as poster at ESMO 2019)
- 6) Galli G, Fabbri A, Ferrara R, Prelaj A, Proto C, Signorelli D, **De Toma A**, Pagani F, Zilembo N, Ganzinelli M, Pruneri G, de Braud FGM, Garassino MC, Lo Russo G. Accuracy of pathologic evaluation for thymic epithelial tumors in an italian reference centre (Accepted as poster at ESMO 2019)
- 7) Galli G, Ferrara R, Pagani F, **De Toma A**, Lo Russo G, Signorelli D, Prelaj A, Zilembo N, Ganzinelli M, Brich S, Fabbri A, Sangaletti S, Pruneri G, Colombo MP, de Braud FGM, Garassino MC, Proto C. Prognostic role of CD73 in metastatic non-small cell lung cancer according to the presence of driver alterations. (Accepted as poster at ESMO 2019)
- 8) Mountzios G, Signorelli D, Rey Cobo J, Banini M, Economopoulou P, Lo Russo G, Baxevas PT, Roila F, **De Toma A**, Banna G, Christopoulou A, Jimenez B, Linardou H, Calles A, Galetta D, Addeo A, Camerini A, Kosmidis PA, Garassino MC, Metro G. Pembrolizumab frontline monotherapy in patients with NSCLC and high PD-L1 expression: Real-world data from a European Cohort with focus on subgroups of interest (Accepted as poster at ESMO 2019)
- 9) Galli G, Proto C, Signorelli D, Imbimbo M, Ferrara R, Prelaj A, **De Toma A**, Randon G, Trevisan B, Ganzinelli M, Zilembo N, Garassino MC, Lo Russo G. Characterization of patients with metastatic non-small cell lung cancer obtaining long term benefit from immunotherapy (Accepted as poster at ESMO 2019)
- 10) Randon G, Galli G, **De Toma A**, Pagani F, Trevisan B, Signorelli D, Proto C, Prelaj A, Ferrara R, Ganzinelli M, Pallavicini L, Di Mauro R, Zilembo N, de Braud F, Garassino MC, Lo Russo G. Salvage chemotherapy after immunotherapy failure in non-small-cell lung cancer patients (Accepted as poster at WCLC 2019)
- 11) Metro G, Signorelli D, Rey-Cobo J, Banini M, Economopoulou P, Lo Russo G, Baxevas P, Roila F, **De Toma A**, Banna G, Christopoulou P, Jimenez B, Collazo-Lorduy A, Linardou H, Calles-Blanco A, Galetta D, Addeo A, Camerini A, Kosmidis P, Garassino M, Mountzios G. Post-progression outcomes after pembrolizumab in patients with NSCLC and high PD-L1 expression: real-world data from an european cohort (Accepted as poster at WCLC 2019)
- 12) Galli G, Imbimbo M, Busico A, Perrone F, Tamborini E, Fabbri A, Marano G, Biganzoli D, Ferrara R, Lo Russo G, Prelaj A, Proto C, Zilembo N, **De Toma A**, Pagani F, Randon G, Ganzinelli M, Biganzoli E, Pruneri G, de Braud F, Garassino M, Signorelli D. Clinical and biological characterization of lung enteric adenocarcinoma. (Accepted as poster at WCLC 2019)
- 13) Prelaj A, Proto C, Lo Russo G, Signorelli D, Ferrara R, Mensah M, Galli G, **De Toma A**, Randon G, Pagani F, Brambilla M, Trevisan B, Ganzinelli M, Zilembo N, de Braud F, Torri V, Garassino M, Sozzi G, Boeri M. MA03.10. Prospective evaluation of a prognostic clinico-molecular score (DEMO) to predict outcome of advanced NSCLC patients treated with immunotherapy. (Accepted as poster at WCLC 2019)

- 14) Galli G, **De Toma A**, Pagani F, Randon G, Trevisan B, Prelaj A, Ferrara R, Proto C, Signorelli D, Ganzinelli M, Zilembo N, de Braud F, Garassino MC, Lo Russo G. P1.04-38. Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer. (Accepted as poster at WCLC 2019)
- 15) **De Toma A**, Lo Russo G, Proto C, Signorelli D, Ferrara R, Prelaj A, Galli G, Pagani F, Trevisan B, Zilembo N, Ganzinelli M, De Braud F, Garassino M.C. Influenza vaccine in non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs): a single institution experience. (Accepted as poster at AIOM 2019)
- 16) Pagani F, **De Toma A**, Randon G, Signorelli D, Lo Russo G, Proto C, Prelaj A, Galli G, Zilembo N, Ganzinelli M, Sangaletti S, Colombo M.P, Campochiaro C, Sica A, De Luca G, Broggin M, Trevisan B, De Braud F, Garassino M.C., Ferrara R. Cyclooxygenase (COX) inhibition impacts the efficacy of first-line single agent PD-1/PD-L1 inhibitors (ICI) in advanced non-small cell lung cancer (aNSCLC) patients (pts). (Accepted as poster at AIOM 2019)
- 17) Signorelli D, Brambilla M, Ferrara R, Proto C, Lo Russo G, Imbimbo M, Galli G, Pagani F, **De Toma A**, Fuca' G, Randon G, Trevisan B, Ganzinelli M, Zilembo N, Fabbri A, De Braud F, Garassino MC, Prelaj A. Immune-checkpoint inhibitors in non-small cell lung cancer with uncommon histologies (Accepted as poster at AIOM 2019)
- 18) Ferrara R, Proto C, Lo Russo G, Signorelli D, Prelaj A, Galli G, Zilembo N, **De Toma A**, Viscardi G, Lobefaro R, Brambilla M, Ganzinelli M, Molino G, Talarico G, Garassino MC, Colombo MP, Sangaletti S. Abstract 4480: Circulating and tumor associated neutrophil subtypes correlate with hyperprogressive disease (HPD) upon immunecheckpoint inhibitors (ICI) in advanced non-small cell lung cancer (aNSCLC) patients (pts) and in vivo models. Presented at AACR 2020 annual meeting
- 19) Horn L, Whisenant JG, Torri V, Huang LC, Trama A, Paz-Ares LG, Felip E, Pancaldi V, **De Toma A**, Tiseo M, Garrido P, Genova C, Cadranet J, Michielin O, Dingemans AMC, Van Meerbeek J, Barlesi F, Wakelee H, Peters S, Garassino MC. Thoracic cancers International COVID-19 collaboration (TERAVOLT): impact of type of cancer therapy and COVID therapy survival. *Journal of Clinical Oncology* 2020; 38(18_suppl):LBA111-LBA111
- 20) Lobefaro R, Viscardi G, Di Liello R, Massa G, Iacovino ML, Sparano F, Ferrara R, Signorelli D, Proto C, Prelaj A, Galli G, De Toma A, Brambilla M, Ganzinelli M, Trevisan B, Bottiglieri A, de Braud FG, Morgillo F, Garassino MC, Lo Russo G. Efficacy and safety of immunotherapy in non-small cell lung cancer patients with poor performance status. *Journal of clinical oncology* 2020; 38 (15_suppl): e21601-e21601
- 21) Ferrara R, Lo Russo G, Signorelli D, Proto C, Prelaj A, Galli G, **De Toma A**, Viscardi G, Lobefaro R, Brambilla M, Talarico G, Bassani B, Spanò SM, Molino G, Zilembo N, Ganzinelli M, Vitale S, Colombo MP, Garassino MC, Sangaletti S. Circulating and tumor-associated neutrophil subtype discriminated hyperprogressive disease (HPD) from conventional progression (PD) upon immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (NSCLC) patients (pts) and in vivo models. *J Clin Oncol* 38: 2020 (suppl; abstr 9547); doi 10.1200/JCO.2020.38.15_suppl.9547
- 22) Addeo A, Metro G, Signorelli D, Economopoulou P, Roila F, Banna GL, **De Toma A**, Camerini A, Christopoulou A, Lo Russo G, Galetta D, Jimenez Munarriz B, Collazo A, Calles A, Baxenavos P, Linardou H, Kosmidis PA, Mountzios GS, Garassino MC, Friedlander A. Poor performance status and front-line pembrolizumab in advanced non-small cell lung cancer (NSCLC) patients with PD-L1>50%. *J Clin Oncol* 38: 2020 (suppl; abstr e21651); doi 10.1200/JCO.2020.38.15_suppl.e21651
- 23) Brambilla M, Nichetti F, Lobefaro R, Galli G, **De Toma A**, Viscardi G, Prelaj A, Ferrara R, Proto C, Signorelli D, Bottiglieri A, Massa G, Trevisan B, Ganzinelli M, Zilembo N, de Braud F, Garassino M, Lo Russo G. 1312P- Chemotherapy followed by immunotherapy compared to reverse sequence in NSCLC with PD-L1 low expression: PFS2 analysis. E-Poster display; *Annals of Oncology* (2020) 31 (suppl_4): S754-S840. 10.1016/annonc/annonc283
- 24) Prelaj A, Bottiglieri A, Proto C, Lo Russo G, Signorelli D, Ferrara R, Galli G, **De Toma A**, Viscardi G, Brambilla M, Lobefaro R, Manglaviti S, Occhipinti M, Labianca A, Gallucci R, Molino G, Zilembo N, Greco FG, Torri V, Garassino MC. 1388 P- Poziotinib in advanced NSCLC with EGFR or HER2 exon 20 insertion mutation: initial results from a single site expanded access program. E-Poster display; *Annals of Oncology* (2020) 31 (suppl_4): S754-S840. 10.1016/annonc/annonc283
- 25) Ferrara R, Facchinetti F, Calareso G, Kasraoui I, Signorelli D, Proto C, Prelaj A, Naltet

- C, Lavaud P, Desmaris R, Viscardi G, Galli G, **De Toma A**, Martinetti A, Barlesi F, Planchard D, Soria J, Garassino MC, Besse B, Lo Russo G. 1278 P- Hyperprogressive disease (HPD) upon first-line PD-1/PD-L1 inhibitors (ICI) as single agent or in combination with platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients. E-Poster display; Annals of Oncology (2020) 31 (suppl_4): S754-S840. 10.1016/annonc/annonc283
- 26) Lobefaro R, Viscardi G, Di Liello R, Massa G, Iacovino ML, Sparano F, Della Corte CM, Ferrara R, Signorelli D, Proto C, Prelaj A, Galli G, **De Toma A**, Brambilla M, Ganzinelli M, Trevisan B, de Braud FGM, Morgillo F, Garassino MC, Lo Russo G. 1329 P- Immune checkpoints inhibitors in advanced NSCLC patients with poor performance status: the role of clinical – pathological variables and inflammatory biomarkers in a real world experience. E-Poster display; Annals of Oncology (2020) 31 (suppl_4): S754-S840. 10.1016/annonc/annonc283
- 27) Ferrara R, Jachetti E, Calareso G, Brambilla M, Lo Russo G, Proto C, Prelaj A, Signorelli D, Galli G, **De Toma A**, Occhipinti M, Manglaviti S, Labianca A, Ganzinelli M, Spanò S, Molino G, Martinetti A, Greco F, Bini M, Beninato T, de Braud F, Colombo MP, Garassino MC, Sangaletti S. Abstract 1669: immunometabolism of circulating neutrophils in hyperprogressive disease (HPD) upon first-line PD-1/PD-L1 inhibitors (ICI) alone or in combination with platinum-based chemotherapy (PCT) in non-small cell lung cancer (NSCLC) patients (PTS). AACR meeting 2021
- 28) Zattarin E, Manglaviti S, Galli E, Apollonio G, Beninato T, Mazzeo L, Massa G, Bottiglieri A, Ganzinelli M, Proto C, Ferrara R, Prelaj A, Galli G, **De Toma A**, Brambilla M, Occhipinti M, Garassino M, de Braud F, Lo Russo G. 1311P The role of inflammatory biomarkers in advanced non-small cell lung cancer patients treated with chemoimmunotherapy. Annals of oncology 2021; 32:S1010-S1011
- 29) Viscardi G, Simeon V, Massari F, Alfieri S, Albertini M, Imbimbo M, Mollica V, Rizzo A, Comitto F, Lo Russo G, Proto C, Prelaj A, Galli G, **De Toma A**, Tralongo A, Cinquini M, Morgillo F, Garassino MC, Torri V, Ferrara R. 1830P Early deaths (ED) upon first-line immunecheckpoint inhibitors (ICI) alone or combined to other non-ICI drugs across solid cancers: a systematic review and meta-analysis. Annals of oncology 2021; 32:1239
- 30) Prelaj A, Bottiglieri A, Lo Russo G, Ferrara R, Galli G, **De Toma A**, Brambilla M, Occhipinti M, Manglaviti S, Beninato T, Zattarin E, Apollonio G, Massa G, Mazzeo L, Galli E, Dumitrescu AD, Ganzinelli M, Gallucci R, Di Mauro RM, Vitale S, de Braud F, Garassino MC, Proto C. P50.06 First-line therapy in NSCLC harbouring EGFR or HER2 exon 20 insertion mutation. Hunting for the best candidate. Journal of thoracic oncology 2021; 16(10): S1116-S1117
- 31) Beninato T, Manglaviti S, Zattarin E, Apollonio G, Galli E, Bini M, Sposetti C, Massa G, Bottiglieri A, Ganzinelli M, Proto C, Ferrara R, Prelaj A, Galli G, **De Toma A**, Brambilla M, Occhipinti M, de Braud G, Garassino M, Lo Russo G. P40.19 Efficacy and toxicity of third-line chemotherapy in advanced non-small cell lung cancer. Journal of thoracic oncology 2021; 16(10):S1078
- 32) Manglaviti S, Bini M, Apollonio G, Galli G, Labianca A, Zecca E, Brambilla M, Occhipinti M, Proto C, Prelaj A, Signorelli D, **De Toma A**, Viscardi G, Beninato T, Zattarin E, Mazzeo L, Galli E, Ganzinelli M, de Braud F, Garassino MC, Lo Russo G, Ferrara R. P40-08 Bone-targeted agents improves survival in high bone tumor burden advanced non-small-cell lung cancer patients treated with PD-(L)1 inhibitors. Journal of thoracic oncology 2021; 16(10):S1072
- 33) Ferrara R, Lo Russo G, Jachetti E, Calareso G, Proto C, Prelaj A, Galli G, Signorelli D, Brambilla M, **De Toma A**, Occhipinti M, Manglaviti S, Apollonio G, Mazzeo L, Ganzinelli M, Martinetti A, de Braud FGM, Garassino M, Colombo M, Sangaletti S. 15 First-line patients platinum- based chemotherapy combined with PD-1/PD-L1 inhibitors (ICI) prevents hyperprogression in non-small cell lung cancer (NSCLC) patients by reducing circulating immature neutrophils. Journal for immunotherapy of cancer 2021; Suppl 2, A16-17

“Cocktail with science – The best of the year in lung cancer” 7th 8th September 2020, Milan

“Trattamento del NSCLC non resecabile in stadio III: opportunità e criticità nell'era post-

PACIFIC”, 1st October 2021, Milan

“Lung Cancer, cocktail with science – Virtual conference 2021” 14th October 2021, Milan

Clinical Trials e Protocolli

Esperienza come Sub-Investigator in più di 30 Clinical Trial di fase II e III

Conferenze e Seminari

Dal 2011 al 2021 partecipazione a più di 40 congressi e seminari italiani ed internazionali trattanti l'Oncologia Medica (Ricerca di base, epidemiologia, diagnosi e terapia)

Certificazioni

Training Certificate of Good Clinical Practice (GCP)

Training certificate of Basic Life Support (BLS-D)

Memberships

Full Members of European Society for Medical Oncology (ESMO)

Full Members of Associazione Italiana Oncologia Medica (AIOM)

Membro dello steering committee per “International registry on thoracic cancer patients with COVID-19 TERA-VOLT (Thoracic cancer international coVID 19 cOLlaboraTion)”

Ai sensi degli artt.11 e 13 del D.lgs. n. 196/2006, si informa che i dati personali raccolti con la presente dichiarazione possono essere utilizzati esclusivamente per finalità connesse al procedimento per il quale sono stati acquisiti. Potranno essere comunicati ad altra P.A. o diffusi solo nei casi previsti da leggi o regolamenti. La comunicazione ad altra P.A. è inoltre consentita quando è comunque necessaria per lo svolgimento di funzioni istituzionali. Inoltre, in relazione al trattamento dei dati personali, l'interessato gode dei diritti di cui all'art. 7 del D.lgs. n. 196/2003.

Milano 23/01/2024

FIRMATO

ALESSANDRO DE TOMA